Otsuka Pharmaceuticals UK Ltd

3 articles about Otsuka Pharmaceuticals UK Ltd

• 

  Medimetriks and Otsuka’s Difamilast Hits Mark in Atopic Dermatitis Trials

  3/27/2020

  Difamilast is a novel atopic dermatitis compound discovered by Otsuka.

• Medimetriks Announces that Otsuka Achieved Positive Top-Line Phase 3 Results for MM36 (difamilast) in Japanese Adult and Pediatric Atopic Dermatitis Patients

  3/26/2020

  Medimetriks Pharmaceuticals, Inc. today announced that its partner, Otsuka Pharmaceuticals Co. Ltd., achieved positive results in two Phase 3 Japanese clinical trials in adult and pediatric patients for MM36 (difamilast), a novel topical, non-steroidal phosphodiesterase IV (PDE4) inhibitor for the treatment of mild to moderate atop

• One Mind Announces Request for Proposals for Five New $250,000 Rising Star Research Awards

  3/25/2019

  Given the growing challenges of addressing brain illness and injury, One Mind, in collaboration with Janssen Research & Development LLC, Otsuka Pharmaceuticals, Kaiser Permanente, the Gifford Foundation, and Bettina Bryant, is offering up to five Rising Star Research Awards in 2019.